Outcomes based on FISH risk among patients eligible for ASCT
| Reference (trial) . | FISH . | Regimen . | HR-FISH/ SR-FISH (N) . | 3-y PFS, % . | 3-y OS, % . | ||
|---|---|---|---|---|---|---|---|
| HR-FISH . | SR-FISH . | HR-FISH . | SR-FISH . | ||||
| 24 (GEM05MENOS65) | HR* | VBMCP/VBAD → Bz × 2 → ASCT × 1 → 3 y maintenance | 18/111 | 39 | 50 | 48 | 84 |
| TD → ASCT × 1 + 3 y maintenance† | 17/110 | 24 | 43 | 56 | 85 | ||
| VTD →ASCT × 1+ 3 y maintenance† | 18/112 | 47 | 54 | 60 | 88 | ||
| 25 (MRC IX intensive) | HR‡ | CVAD → ASCT × 1 | 141/166 | 18§ | 32§ | 58 | 81 |
| CTD → ASCT × 1 | 152/167 | 20§ | 34§ | 59 | 82 | ||
| 29 (RV-MM-EMN-441) | HR* | Rd → CRD → Len ± prednisone | 30/57 | 17 | 51 | 67 | 92 |
| Rd → ASCT × 2 → Len ± prednisone | 23/70 | 43 | 59 | 78 | 88 | ||
| 30 (IFM-99) | t(4;14) | VAD → ASCT × 2 | 100/616 | 23 | 50 | 58 | 80 |
| 27 (IFM 2005-01) | t(4;14) | VAD → ASCT × 1 or 2 ± Len maintenance | 98/414 | 17 | N/A | 32‖ | 72‖ |
| VD → ASCT × 1 or 2 ± Len maintenance | 106/401 | 36 | N/A | 63 | 85 | ||
| 26 (GIMEMA MM-BO2005) | t(4;14) | TD → ASCT × 2 → TD → Dex | 57/181 | 37 | 63 | N/A | N/A |
| VTD → ASCT × 2 → VTD → Dex | 53/183 | 69 | 74 | N/A | N/A | ||
| 28 (HOVON65/GMMG-HD4) | t(4;14) | VAD → ASCT × 1 or 2 → Thal maintenance | 35/227 | 20 | 40 | 40 | 73 |
| PAD → ASCT × 1 or 2 → Bz maintenance | 35/215 | 28 | 48 | 60 | 79 | ||
| 31, 32 (IFM-2005-02) | t(4;14) | No Len maintenance post-ASCT | N/A | 15‖ | N/A | N/A | N/A |
| Len maintenance post-ASCT | 26/229 | 27¶ | 42¶ | N/A | N/A | ||
| 27 (IFM 2005-01) | Del(17p) | VAD → ASCT × 1 or 2 ± Len maintenance | 119/393 | 21 | N/A | 41 | N/A |
| VD→ ASCT × 1 or 2 ± Len maintenance | 54/427 | 21 | N/A | 68 | 82 | ||
| 30 (IFM-99) | Del(17p) | VAD → ASCT × 2 | 58/474 | 25 | 49 | 50 | 78 |
| 28 (HOVON65/GMMG-HD4) | Del(17p) | VAD → ASCT × 1 or 2 → Thal maintenance | 40/273 | 14 | 41 | 17 | 80 |
| PAD → ASCT × 1 or 2 → Bz maintenance | 25/264 | 32 | 48 | 66 | 80 | ||
| 31, 32 (IFM-2005-02) | Del(17p) | Len maintenance post-ASCT | 30/235 | 29¶ | 42¶ | N/A | N/A |
| No Len maintenance post-ASCT | N/A | 14¶ | N/A | N/A | N/A | ||
| Reference (trial) . | FISH . | Regimen . | HR-FISH/ SR-FISH (N) . | 3-y PFS, % . | 3-y OS, % . | ||
|---|---|---|---|---|---|---|---|
| HR-FISH . | SR-FISH . | HR-FISH . | SR-FISH . | ||||
| 24 (GEM05MENOS65) | HR* | VBMCP/VBAD → Bz × 2 → ASCT × 1 → 3 y maintenance | 18/111 | 39 | 50 | 48 | 84 |
| TD → ASCT × 1 + 3 y maintenance† | 17/110 | 24 | 43 | 56 | 85 | ||
| VTD →ASCT × 1+ 3 y maintenance† | 18/112 | 47 | 54 | 60 | 88 | ||
| 25 (MRC IX intensive) | HR‡ | CVAD → ASCT × 1 | 141/166 | 18§ | 32§ | 58 | 81 |
| CTD → ASCT × 1 | 152/167 | 20§ | 34§ | 59 | 82 | ||
| 29 (RV-MM-EMN-441) | HR* | Rd → CRD → Len ± prednisone | 30/57 | 17 | 51 | 67 | 92 |
| Rd → ASCT × 2 → Len ± prednisone | 23/70 | 43 | 59 | 78 | 88 | ||
| 30 (IFM-99) | t(4;14) | VAD → ASCT × 2 | 100/616 | 23 | 50 | 58 | 80 |
| 27 (IFM 2005-01) | t(4;14) | VAD → ASCT × 1 or 2 ± Len maintenance | 98/414 | 17 | N/A | 32‖ | 72‖ |
| VD → ASCT × 1 or 2 ± Len maintenance | 106/401 | 36 | N/A | 63 | 85 | ||
| 26 (GIMEMA MM-BO2005) | t(4;14) | TD → ASCT × 2 → TD → Dex | 57/181 | 37 | 63 | N/A | N/A |
| VTD → ASCT × 2 → VTD → Dex | 53/183 | 69 | 74 | N/A | N/A | ||
| 28 (HOVON65/GMMG-HD4) | t(4;14) | VAD → ASCT × 1 or 2 → Thal maintenance | 35/227 | 20 | 40 | 40 | 73 |
| PAD → ASCT × 1 or 2 → Bz maintenance | 35/215 | 28 | 48 | 60 | 79 | ||
| 31, 32 (IFM-2005-02) | t(4;14) | No Len maintenance post-ASCT | N/A | 15‖ | N/A | N/A | N/A |
| Len maintenance post-ASCT | 26/229 | 27¶ | 42¶ | N/A | N/A | ||
| 27 (IFM 2005-01) | Del(17p) | VAD → ASCT × 1 or 2 ± Len maintenance | 119/393 | 21 | N/A | 41 | N/A |
| VD→ ASCT × 1 or 2 ± Len maintenance | 54/427 | 21 | N/A | 68 | 82 | ||
| 30 (IFM-99) | Del(17p) | VAD → ASCT × 2 | 58/474 | 25 | 49 | 50 | 78 |
| 28 (HOVON65/GMMG-HD4) | Del(17p) | VAD → ASCT × 1 or 2 → Thal maintenance | 40/273 | 14 | 41 | 17 | 80 |
| PAD → ASCT × 1 or 2 → Bz maintenance | 25/264 | 32 | 48 | 66 | 80 | ||
| 31, 32 (IFM-2005-02) | Del(17p) | Len maintenance post-ASCT | 30/235 | 29¶ | 42¶ | N/A | N/A |
| No Len maintenance post-ASCT | N/A | 14¶ | N/A | N/A | N/A | ||
OS and PFS are estimated when necessary from Kaplan-Meier survival curves in an effort to normalize results to 3-y outcomes.
Bz, bortezomib; CRD, carfilzomib-revlimid-dexamethasone; Dex, dexamethasone; Len, lenalidomide; PAD, bortezomib-doxorubicin-dexamethasone; TD, thalidomide-dexamethasone; Thal, thalidomide; VAD, vincristine-adriamycin-dexamethasone; VBAD, vincristine-BCNU-doxorubicin-dexamethasone; VD, bortezomib-dexamethasone; VTD, velcade-thalidomide-dexamethasone.
HR: Any of the following: t(4;14), t(14;16), or del(17p13).
Secondary randomization to 1 of 3 maintenance regimens: interferon, thalidomide, or bortezomib + thalidomide.
HR: Any of the following: gain(1q), t(4;14), t(14;20), t(14;16), del(17p13), and del (1p32).
Median PFS, in months.
4-year OS from maintenance randomization, %.
Median PFS from maintenance randomization, month.